Palbociclib - Onyx Pharmaceuticals/Pfizer
Alternative Names: IBRANCE; Ibrance; Iburance; Parvociclib; PD-0332991; PD-332991; PD-991; PF-332991Latest Information Update: 10 Jul 2024
At a glance
- Originator Onyx Pharmaceuticals; Pfizer; SOLTI Breast Cancer Research Group
- Developer Assistance Publique Hopitaux de Paris; Bergonie Institute; Calithera Biosciences; Canadian Cancer Trials Group; Celgene Corporation; Dana-Farber Cancer Institute; Emory University; European Organisation for Research and Treatment of Cancer; Georgetown University; German Breast Group; Grupo Espanol de Tumores Neuroendocrinos; GSK; International Breast Cancer Study Group; iOMEDICO AG; Karolinska Institute; National Cancer Institute (USA); Northwestern University; Pfizer; UNC Lineberger Comprehensive Cancer Center; UNICANCER; University of California at San Francisco; University of Texas M. D. Anderson Cancer Center; Washington University School of Medicine
- Class 2 ring heterocyclic compounds; Antineoplastics; Cyclopentanes; Ketones; Piperazines; Pyridines; Pyrimidines; Small molecules
- Mechanism of Action Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Breast cancer
- Phase III HER2 negative breast cancer
- Phase II/III Non-small cell lung cancer
- Phase II Bone metastases; Brain metastases; Gastrointestinal stromal tumours; Mantle-cell lymphoma; Pancreatic cancer; Prostate cancer; Squamous cell cancer; Urogenital cancer
- Phase I/II Colorectal cancer; Malignant melanoma
- No development reported Acute myeloid leukaemia; Glioblastoma; Multiple myeloma; Precursor cell lymphoblastic leukaemia-lymphoma; Solid tumours
- Discontinued Astrocytoma; Glioma
Most Recent Events
- 31 May 2024 Efficacy and adverse events data from a phase Ib trial in Breast cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 16 May 2024 Updated efficacy, pharmacodynamics and adverse event data from the phase I/II VERITAC trial in HER2-negative-breast-cancer released by Arvinas
- 01 Mar 2024 University of Kansas Medical Center and Pfizer terminate a phase I/II trial in HER2-positive Breast Cancer in USA (PO) due to low accrual (NCT03709082)